That said, limited supply of GLP-1s amid soaring demand, as well as the accompanying steep price tag, are constraints
The most common adverse effectsnausea, diarrhea, vomiting, and constipationtypically diminish over time as patients acclimate to the medication
Generally, we advise them to anticipate losing around 2-3 pounds per week in the initial 4-6 weeks, which may gradually decrease to 1-2 pounds per week
Introduction When starting tirzepatide for medical weight management, one of the most important parts of treatment is the titration schedule the gradual process of increasing the dose over time
It is also widely studied for cardiovascular benefits: the SELECT trial reported a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and existing cardiovascular disease
On the other hand, the dual GLP-1-glucose-dependent insulinotropic peptide (GIP) receptor agonist LY3298176 (Tirzepatide) provided substantial and sustained reductions in body weight in a 72-week trial in individuals with obesity 19
